Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
CSPC Pharmaceutical Group ( (HK:1093) ) has shared an announcement.
CSPC Pharmaceutical Group has received marketing approval from China’s National Medical Products Administration for its new chemical drug, Prusogliptin Tablets, branded as Shanzeping. This drug is designed to improve glycemic control in adults with type 2 diabetes by enhancing insulin secretion and lowering blood glucose levels, offering a new treatment option and enriching the company’s product portfolio in metabolism.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong-based company operating in the pharmaceutical industry. It specializes in the development and production of pharmaceutical products, focusing on innovative drugs and healthcare solutions.
YTD Price Performance: -5.76%
Average Trading Volume: 7,366
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.52B
For detailed information about 1093 stock, go to TipRanks’ Stock Analysis page.
